Cingulate_Logo_400x400_twitter.jpg
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
September 12, 2024 08:30 ET | Cingulate Inc.
KANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Entero-Logo-Options-FINAL.png
Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
September 10, 2024 07:00 ET | Entero Therapeutics, Inc.
BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Pfizer und BioNTech
Pfizer und BioNTech geben Update zu mRNA-basiertem Kombinationsimpfstoffprogramm gegen Grippe und COVID-19 bei Personen im Alter von 18 bis 64 Jahren bekannt
August 16, 2024 06:45 ET | BioNTech SE
Pfizers und BioNTechs Kombinationsimpfstoffkandidat gegen Grippe und COVID-19 hat in einer Phase-3-Studie eines ihrer beiden primären Ziele zur Immunogenität erreichtDie Studie erreichte eines ihrer...
Pfizer and BioNTech
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
August 16, 2024 06:45 ET | BioNTech SE
 In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectivesThe trial did not meet one of its primary...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved
August 13, 2024 07:45 ET | Cingulate Inc.
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 targeted in 1H 2025Licensing Activity Continues KANSAS CITY, Kan., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a...
Alumis.png
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
July 29, 2024 08:00 ET | Alumis Inc.
Alumis announced that patient dosing has commenced in the ONWARD Phase 3 clinical program for ESK-001 for the treatment of psoriasis.
Moonlake logo.png
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
June 10, 2024 08:00 ET | MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis Builds upon the positive...
Celcuity+Logo.jpg
Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing
May 30, 2024 07:00 ET | Celcuity Inc.
The Phase 3 clinical trial will evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer who are endocrine therapy...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
May 24, 2024 08:00 ET | Genelux Corporation
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
May 23, 2024 16:01 ET | Genelux Corporation
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants